MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/rmdopen-2022-002859

Медицинская библиотека · RMD open · 2023

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.

Khanna Dinesh, Maher Toby M, Volkmann Elizabeth R, Allanore Yannick, Smith Vanessa, Assassi Shervin, Kreuter Michael, Hoffmann-Vold Anna-Maria, Kuwana Masataka, Stock Christian, Alves Margarida, Sambevski Steven, Denton Christopher P

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

To investigate the rate of decline in forced vital capacity (FVC), and the effect of nintedanib on the rate of decline in FVC, in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who had risk factors for rapid decline in FVC.

METHODS

The SENSCIS trial enrolled subjects with SSc and fibrotic ILD of ≥10% extent on high-resolution CT. The rate of decline in FVC over 52 weeks was analysed in all subjects and in those with early SSc (<18 months since first non-Raynaud symptom), elevated inflammatory markers (C reactive protein ≥6 mg/L and/or platelets ≥330×109/L) or significant skin fibrosis (modified Rodnan skin score (mRSS) 15-40 or mRSS ≥18) at baseline.

RESULTS

In the placebo group, the rate of decline in FVC was numerically greater in subjects with <18 months since first non-Raynaud symptom (-167.8 mL/year), elevated inflammatory markers (-100.7 mL/year), mRSS 15-40 (-121.7 mL/year) or mRSS ≥18 (-131.7 mL/year) than in all subjects (-93.3 mL/year). Nintedanib reduced the rate of FVC decline across subgroups, with a numerically greater effect in patients with these risk factors for rapid FVC decline.

CONCLUSION

In the SENSCIS trial, subjects with SSc-ILD who had early SSc, elevated inflammatory markers or extensive skin fibrosis had a more rapid decline in FVC over 52 weeks than the overall trial population. Nintedanib had a numerically greater effect in patients with these risk factors for rapid ILD progression.

Для цитирования: Khanna Dinesh, Maher Toby M, Volkmann Elizabeth R, Allanore Yannick, Smith Vanessa, Assassi Shervin, Kreuter Michael, Hoffmann-Vold Anna-Maria, Kuwana Masataka, Stock Christian, Alves Margarida, Sambevski Steven, Denton Christopher P. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.. RMD open. 2023. DOI: 10.1136/rmdopen-2022-002859.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.